Milestone demonstrates the growing customer adoption of the Company’s proprietary technology Milestone demonstrates the growing customer adoption of the Company’s proprietary technology

The rest is here:
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

WINTER PARK, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition is excited to announce the installation of an exclusive artwork by the renowned performance artist and speed painter, Rock Demarco, at its clinic. This unique piece, which blends painting with 3D sculptural elements, now adorns the clinic's main reception area, symbolizing transformation and rebirth through the poignant imagery of butterflies and stem cells. After his initial visit to the clinic, Rock Demarco felt deeply inspired and decided to donate this custom piece to Adia Nutrition.

Visit link:
Adia Nutrition Unveils Exclusive Artwork by Renowned Performance Artist Rock Demarco at First Clinic

ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that on December 16, 2024, the Company received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice indicated that trading in the Company’s shares of common stock (the “Common Stock”) on Nasdaq will be suspended effective at the open of trading on Wednesday, December 18, 2024.

See original here:
Vaccinex Announces Receipt of Delisting Notification from Nasdaq

SAN FRANCISCO and KIGALI, Rwanda, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Bio Usawa, Inc., a leading biotechnology company committed to delivering affordable and accessible monoclonal antibody-based therapies for cancer, ophthalmic, autoimmune, and infectious diseases in Africa, has named Mr. Eric Karikari-Boateng its Head of Global Regulatory Strategy.

Follow this link:
Bio Usawa Names Former Ghana Food and Drug Authority Director Eric Karikari-Boateng as Head of Global Regulatory Strategy

PRESS RELEASE

Original post:
AB Science provides a summary of the webcast held on December 16, 2024

IRVINE Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the Company's stock has resumed trading under the symbol NYMXF on the Over the Counter QB (OTCQB®) Venture Market. This is a higher level tier from the Company's prior listing. With the new OTCQB listing, Nymox’s stock is now eligible for proprietary broker-dealer quotations.

View original post here:
NYMOX Announces Trading Resumed and New Listing on OTCQB Market

Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS ("Zelluna"), the fully committed private placement (the "Private Placement"), and the intention to carry out a subsequent repair offering (the "Subsequent Offering") of up to 3,846,153 new shares at a subscription price per new share of NOK 2.60, directed towards shareholders of Ultimovacs or Zelluna as of close of trading on 17 December 2024 who (i) were not allocated shares in the Private Placement; (ii) were not offered to provide pre-commitments for the Private Placement; and (iii) are not resident in a jurisdiction where such offering would be unlawful or would (in jurisdictions other than Norway) require any prospectus, filing, registration or similar action.

Read this article:
Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA

Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement (the "Private Placement" and together with the Business Combination, the "Transactions").

Read the original post:
Ultimovacs ASA – Mandatory notification of trade 

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, “Pioneering the Economics of Health: Balancing Access and Outcomes,” during the 43rd Annual J.P. Morgan Healthcare Conference.

Link:
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare...

Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024 Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024

Go here to see the original:
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18,...

Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans

More here:
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, has been invited to present a corporate overview, and will engage, with Inventiva’s leadership team, in investor meetings at the upcoming 43rd Annual J.P. Morgan Annual Healthcare Conference, being held on January 13-16, 2025 at the Westin St. Francis in San Francisco, California.

Read the original:
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector

View original post here:
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic...

PARIS and CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced a virtual event titled "Accelerating the Future of Nanotherapeutics," scheduled to take place at 9:00 AM ET / 3:00 PM CET on Thursday, December 19, 2024.

Go here to see the original:
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

Up to $200 million financing, includes $50 million upfront Up to $200 million financing, includes $50 million upfront

Read more from the original source:
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.

The rest is here:
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

A Plan for Compliance has been Undertaken A Plan for Compliance has been Undertaken

Continued here:
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company (“Odyssey”) dated May 29, 2023 (the “Indenture”), certain holders (each, a “Debentureholder”) of 12.0% unsecured convertible debentures of the Company (the “Debentures”) have elected to receive common shares of the Company (the “Common Shares”) in lieu of cash in partial satisfaction of an aggregate total of approximately $91,000 interest payable to all holders of the Debentures on November 28, 2024 (the “Interest Payment Date”) and, in connection therewith, the Company has entered into a debt settlement agreement with Odyssey as of the date hereof. Approximately $20,500 of the interest payable under the Debentures will be settled by the issuance of Common Shares with the remaining amount to be settled in cash.

See the original post here:
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology

Go here to see the original:
NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology

Basel, 18 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE mark approval for its cobas® Mass Spec solution including the cobas® i 601 analyser and the first Ionify® reagent pack of four assays for steroid hormones2. The CE mark is the first milestone in the global launch of the cobas Mass Spec solution, using in-house innovation to bring automated, integrated and standardised clinical mass spectrometry testing to routine laboratories worldwide. Following launch, the cobas Mass Spec solution will roll out a menu offering of more than 60 analytes for testing of steroid hormones, vitamin D metabolites, immunosuppressant drugs (ISD), therapeutic drug monitoring (TDM) and drugs of abuse testing (DAT).

See the original post:
Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution